INTELLIgene Expressions, Inc.
Biologics Contract Manufacturing Organization

- Founded in 1992 with $90,000 personal investment
- Purchased manufacturing equipment from a GMP facility closing in California and shipped it to Alberta, Canada
- Received a land grant from the Province of Alberta and built out a 10,000 square foot biologics contract manufacturing facility
- Became one of the fastest growing companies in Canada employing 24 individuals in a highly specialized field
Avicenna Medica, Inc.

Oncology Company

- Founded in 2000 by way of strategic in-licensing to establish a clinical stage oncology company funded by INTELLIgene’s profits
- Avicenna’s pipeline consisted of a Phase 2 conjugated toxin platform for targeted intracellular delivery of potent cytotoxic agents to tumour cells
- The Company was sold in 2001, along with INTELLIgene, for $90 million to KS Biomedix, a UK based public company (LSE)
Protox Therapeutics Inc.
Publicly Listed (TSX) Biotechnology Company

- Joined as President and CEO in 2005 when Protox was a small pre-clinical stage publicly listed company developing targeted pro-toxins for prostatic disease (localized prostate cancer and BPH)
- Took the program from pre-clinical to completion of five Phase 1 and 2 clinical trials in over 150 patients
- Completed a $75 million licensing deal for development in Japan
- Raised in excess of $70M by way of private placements and public offerings
- Closed $35 million strategic investment by Warburg Pincus and subsequent rebranded as Sophiris Bio (Nasdaq)
Medicenna Therapeutics

CPRIT Funded Immuno-Oncology Company

- Founded in 2011 using personal capital to in-license MDNA55 (IL4 fusion toxin) and purchase historical data package
- Received US$14.1 million grant from CPRIT which allowed MDNA55 to move into the clinic and provided the necessary validation to raise an additional US$11 million in match capital
- Initiated a Phase 2b clinical trial in recurrent glioblastoma with enrolment expected to be complete in Q1 2018
- Completed a reverse takeover transaction in Q1 2017 to become publicly listed on the TSX.V, graduated to the main board of the TSX in Q3 of 2017 and listed on the OTCQX in Q4 2017